iiinova — where your digital self keeps evolving

Journal of Clinical Lipidology @lipidjournal.bsky.social · 29/09/2026

The JCL is pleased to announce two new issues are live! Check out the September Issue and our special Guidelines Issue. 🔗 September: lipidjournal.com/current 🔗 Guidelines: lipidjournal.com/issue/S1933-2874(26)X2010-4

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 24/09/2026

Happy #FHAwarenessDay! What will it take to close the FH care gap? This #JCLSpotlight for #CholesterolMonth says it's multiple strategies working together, not just one fix. #KnowFH Read more: ow.ly/RqYQ50ZQMya

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 23/09/2026

#FHAwarenessDay is 1 day away! This #JCLSpotlight for #CholesterolMonth explores how a structured transition model can help bridge the gap for young FH patients moving from pediatric to adult care. #KnowFH 🔗 ow.ly/AHgs50ZQCsC

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 22/09/2026

2 days until #FHAwarenessDay! Our #JCLSpotlight for #CholesterolMonth highlights how correcting LDL-C for Lp(a) improves FH diagnosis and reduces false positives. #KnowFH Read more: ow.ly/zAN150ZQ9XA

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 17/09/2026

#JCLSpotlight for #CholesterolMonth: Are lipid-lowering drugs safe during pregnancy? This Czech nationwide study offers new insight into maternal and fetal outcomes. Read more: ow.ly/bp4P50ZNRqo

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 15/09/2026

#JCLSpotlight for #CholesterolMonth: New research finds Lp(a) plasma levels have no major effect on coagulation phenotype, though high levels were associated with a mild increase in FV:C. 🔗 ow.ly/e7Eg50ZNsZR

010

Journal of Clinical Lipidology @lipidjournal.bsky.social · 01/09/2026

Happy #CholesterolMonth! All month, we'll be highlighting the latest cholesterol-related research published in the JCL. First up in the #JCLSpotlight, from the Aug Edition: "Recurrence of CV events despite achieving LDL-C <1.4 mmol/L in patients w/ CAD": ow.ly/WP7t50ZHK29

010

Journal of Clinical Lipidology @lipidjournal.bsky.social · 28/08/2026

JCL Roundtable: Lipid metabolism, brain health, and dementia prevention. Recorded at #NLAFall in Scottsdale, Drs. Saeed, Trippi, Palta, Niotis, and Maki dig into this critical topic. Have you read it yet? www.lipidjournal.com/article/S1933-…

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 17/08/2026

#JCLSpotlight: Plasma-based low-grade inflammation & endothelial dysfunction explain a small but significant proportion of the association between n-3 polyunsaturated fatty acids and CV diseases. Read more: ow.ly/zeOq50ZA1V7

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 12/08/2026

The July issue of the JCL is here! Our first #JCLSpotlight: "Unmet needs for lipid management in patients with peripheral arterial disease." Closing the LLT gap could mean better CV outcomes & quality of life for PAD patients. Read more: ow.ly/6gPn50Zz5q1

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 17/07/2026

Upon learning of the JCL's recent Impact Factor increase, we received a thoughtful note from W. Virgil Brown, MD, MNLA, the journal's very first Editor. Few acknowledgments carry more weight than one from the person who built the foundation of our society's journal.

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 16/07/2026

#JCLSpotlight: Over 2 years, treatment with pitavastatin calcium of CDO for adolescents resulted in no changes in vascular measures. Statin therapy safely lowered atherogenic lipid particles, potentially reducing cardiovascular risk. 🔗 ow.ly/QPYp50Znv6J

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 15/07/2026

#JCLSpotlight: Depot-specific metabolic differences are evident in pediatric obesity. vWAT in children with OW/OB shows heightened lipotoxicity & mitochondrial stress, while sWAT exhibits fewer, less pronounced metabolic differences. 🔗 ow.ly/wX6F50Znv5P

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 14/07/2026

#JCLSpotlight: Elevated first-trimester RC is independently associated with increased GDM risk — partially mediated by pre-pregnancy BMI and insulin resistance. Measuring RC early in pregnancy may improve GDM risk identification. 🔗 ow.ly/ixqC50Znv07

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 07/07/2026

#JCLSpotlight: FCS clinical diagnosis scoring systems — including the North American system at threshold 45 — discriminate multifactorial PC from biallelic FCS & may improve equitable access to precision medicine for PC patients. 🔗 ow.ly/vlMk50Zjni2

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 06/07/2026

#JCLSpotlight: In this 10-year study, lipid apheresis was associated with higher odds of ICU admission in patients with HTG-AP. Among LA-treated patients, baseline TG >56.5 mmol/L predicted prolonged hospitalization. 🔗 ow.ly/H1YR50Zjnf0

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 02/07/2026

#JCLSpotlight: In this cohort study, patients with sHTG & eHTG had significantly higher incidence of AP & CV events vs normal TG, with risk increasing stepwise by TG level, especially for AP. 🔗 ow.ly/mer250ZjnaB

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 01/07/2026

The June edition of the JCL is live — have you looked yet? First in the #JCLSpotlight: Could pretreatment LDL-C calculation at trial enrollment identify undiagnosed SH and enable opportunistic FH screening? 🔗 Read more: ow.ly/gYNN50ZiR4c

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 01/06/2026

#JCLSpotlight: SGLT2i use in diabetic CAD patients was associated with modest LDL-C reductions and lower mortality/MACE risk, supporting further evaluation of their lipid-modifying role in secondary prevention. 🔗 ow.ly/OcLV50Z6kBY

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 29/05/2026

#JCLSpotlight: Baseline apoB may drive long-term MACE recurrence in very young ACS survivors, highlighting its potential utility for risk stratification beyond traditional lipid markers. 🔗 ow.ly/VI1T50Z5BiG

100

Journal of Clinical Lipidology @lipidjournal.bsky.social · 27/05/2026

#JCLSpotlight: LPL DNA methylation in adipose tissue differed in patients with PC compared with others, highlighting that different factors might contribute to PC and its associated risks. 🔗 ow.ly/ERfB50Z4HM6

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 22/05/2026

#JCLSpotlight: Two-year pemafibrate treatment significantly improved liver stiffness & hepatic parameters in patients with MASLD, independent of weight loss or fat reduction, suggesting direct antifibrotic mechanisms. 🔗 ow.ly/sjVb50Z3nxF

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 21/05/2026

#JCLSpotlight: Elevated RC baseline levels, variability & cumulative exposure are independently associated with increased stroke risk in patients with AF, underscoring the need for lipid-lowering strategies targeting RC. 🔗 ow.ly/Ghvh50Z2LZ6

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 15/05/2026

The May edition of the Journal of Clinical Lipidology is LIVE & we're starting strong. #JCLSpotlight: Initiating triple LLT at ACS hospitalization may markedly reduce CV events through earlier and more complete LDL-C target achievement. 🔗https://ow.ly/4hxW50Z0nEt

020

Journal of Clinical Lipidology @lipidjournal.bsky.social · 13/05/2026

#JCLSpotlight: Evinacumab achieved up to 82% LDL-C reduction in 2 autosomal recessive hypercholesterolemia cases — both without functional LDL receptors — highlighting the importance of early, intensive therapy. 📄https://ow.ly/gJ9h50YYs8b

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 07/05/2026

#JCLSpotlight: A rare case of Niemann–Pick disease type B with sea-blue histiocytosis presenting as decompensated cirrhosis — where histopathology provided key diagnostic evidence when enzyme and genetic tests were unavailable. 📄 ow.ly/Rtxl50YW1CH

010

Journal of Clinical Lipidology @lipidjournal.bsky.social · 06/05/2026

The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline joins the growing international consensus: Lp(a) should be tested at least once in all adults. Drs. Michael J. Wilkinson and Marlys L. Koschinsky discuss the implications in the JCL 👉 ow.ly/5WKF50YVKjB

010

Journal of Clinical Lipidology @lipidjournal.bsky.social · 05/05/2026

#JCLSpotlight: Repeat Lp(a) testing is generally unnecessary but could be considered in those near risk thresholds or those being evaluated for Lp(a)-lowering therapies. Read more: ow.ly/wZ8T50YV3Jk

001

Journal of Clinical Lipidology @lipidjournal.bsky.social · 04/05/2026

HoFH is the most severe and difficult-to-treat form of FH. On #HoFHAwarenessDay, we invite you to read National Lipid Association's expert clinical consensus on FH in the JCL, including updated guidance on HoFH treatment and management. 🔗https://ow.ly/4ZMu50YTgCk

010

Journal of Clinical Lipidology @lipidjournal.bsky.social · 30/04/2026

#JCLSpotlight: Higher serum AIM levels were associated with altered lipid metabolites and predicted incident dyslipidemia, with the strongest link to elevated LDL-C seen in women. Read more: ow.ly/UUXQ50YSqoC

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 29/04/2026

#JCLSpotlight: PCSK9 inhibition reduces LpPLA₂ and IP-10 without altering the global inflammatory response or HDL antioxidant function, suggesting a decrease in chronic vascular inflammation without broad systemic immune effects. 📄 ow.ly/HuOe50YRPsB

020

Journal of Clinical Lipidology @lipidjournal.bsky.social · 28/04/2026

#JCLSpotlight: PAD carries high cardiovascular risk, yet many patients still don't receive guideline-recommended lipid-lowering therapy. A new narrative review explores the unmet needs and health inequities driving this gap. 📄https://ow.ly/P6kP50YR655

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 27/04/2026

#JCLSpotlight: In a real-world observational study, inclisiran demonstrated significant LDL-C reductions within 1 year. Plus, insights on patient out-of-pocket costs. 👉 Read more: ow.ly/QtnW50YQxgK

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 24/04/2026

#JCLSpotlight: Pemafibrate effectively & safely reduced LDL-C in patients with statin-intolerant hypercholesterolemia and normal triglyceride levels, offering a potential new therapeutic option. Read more: ow.ly/oCrP50YPb1P

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 07/04/2026

#JCLSpotlight: A text-based Health platform showed high interactivity & acceptability for tracking statin-associated muscle symptoms over time. Read more from the study: ow.ly/ECuU50YEFyV

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 02/04/2026

#JCLSpotlight: Elevated Lp(a) was found in 8.3% of the general population & up to 23.9% in those with ASCVD. Adding Lp(a) as a risk enhancer improved risk reclassification beyond HellenicSCOREII+ in two Greek cohorts. Read more: ow.ly/jXMT50YCr6E

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 01/04/2026

#JCLSpotlight: Poor sleep quality is linked to unfavorable lipid profiles, especially elevated sdLDL-C levels. Treating sleep quality as a modifiable lifestyle factor may help reduce lipid abnormalities and prevent CVD. Read more: ow.ly/vayN50YBKQB

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 28/03/2026

#JCLSpotlight | #NationalTriglyceridesDay Rare late-onset FCS case highlights: ▪️ Delayed diagnosis → pancreatic insufficiency and malnutrition ▪️ Statin and pioglitazone withdrawal → improved clinical status ▪️ Volanesorsen → 74% triglyceride reduction from baseline Read: ow.ly/7W9g50YzLPX

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 26/03/2026

#JCLSpotlight from the March Issue: Obese patients with diabetes and CAD who achieved LDL-C <1.8 mmol/L showed greater coronary atheroma regression than nonobese patients. Read more: ow.ly/7V3F50YzlU1

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 24/03/2026

Spotlighting #LpaAwarenessDay with two recent JCL studies on Lp(a) testing: 1️⃣ Barriers & facilitators to Lp(a) testing: ow.ly/Gsmc50Yyich 2️⃣ QI study increases Lp(a) testing in outpatient cardiology clinic: ow.ly/exM350Yyicg #KnowLpa

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 23/03/2026

#JCLSpotlight: Two pediatric cases of early death from FH, alongside a systematic review of childhood and adolescent FH-related deaths, reveal diagnostic delays and inadequate treatment as common contributing factors. Read more about the findings: ow.ly/oG7L50YxyGv

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 20/03/2026

#JCLSpotlight: A rare variant in SCARB1 — p.(Thr378Met) — impairs SR-B1-mediated HDL uptake and is associated with elevated HDL-C levels, supporting SCARB1 as a candidate gene for genetic screening in patients with dyslipidemia. Read more: ow.ly/yPhX50YwXV1

021

Journal of Clinical Lipidology @lipidjournal.bsky.social · 18/03/2026

#JCLSpotlight: The BALANCE study shows olezarsen 80 mg reduced all-cause inpatient service utilization and improved the experience of patients with FCS after just one year of treatment. Read more: ow.ly/AICF50Yw3ea

011

Journal of Clinical Lipidology @lipidjournal.bsky.social · 10/03/2026

The Journal of Clinical Lipidology is growing!📈 Our 2025 CiteScore climbed to 6.8, a reflection of the high-quality research and dedicated community behind every issue. #Lipidology #ClinicalResearch

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 06/03/2026

The JCL February issue is live!📰 First in the #JCLSpotlight: A meta-analysis of 92 studies found carotid plaque in 23% of asymptomatic adults (18–65), rising from 5.2% (18–45) to 30.3% (50–65) and higher in men vs women. Read more: ow.ly/qpxv50YqaC2

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 05/03/2026

The NLA’s newest meta-analysis shows that in CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated w/ a 30% RRR in 4-point MACE. These findings support LDL-C lowering early in the life course: ow.ly/32o050YpGI4

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 04/03/2026

On #WorldObesityDay, we invite you to explore the #JCLSpecialEdition on obesity, which brings together multidisciplinary insights for clinicians, researchers, educators, and public health leaders. Read the issue: lipidjournal.com/issue/S1933-2874(26)X0002-2

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 02/03/2026

#JCLSpecialEdition #Obesity Diagnosis and management of CVD risk factors is an important aspect of an obesity management plan. Evidence shows treatment with liraglutide, semaglutide, and/or bariatric surgery lowers CVD events and mortality. Explore the full findings: ow.ly/LtnK50Yofyb

000

Journal of Clinical Lipidology @lipidjournal.bsky.social · 26/02/2026

#JCLSpecialEdition #Obesity A key characteristic of obesity is adipocytopathic atherogenic dyslipidemia. This review highlights the lipid specialist’s role in team-based obesity care to address cardiometabolic risk and improve long-term outcomes. Read now: ow.ly/GOtQ50YmuEM

010

Journal of Clinical Lipidology @lipidjournal.bsky.social · 25/02/2026

#JCLSpecialEdition #Obesity Childhood obesity is a distinct condition with unique management needs. This review covers rising prevalence, genetic/environmental drivers, comorbidities & current treatments (IHBLT, metabolic surgery & pharmacotherapy). Read now: ow.ly/AMmG50YlV5S

000